Cellectis SA (ALCLS) AI Stock Analysis

• Market Cap: €224.21M
• Dividend Yield: N/A
• Average Volume (3M): 852.48K
• Price to Earnings (P/E): 117.9
• Beta (1Y): 0.56
• Revenue Growth: 150.80%
• EPS Growth: 67.81%
• Country: FR
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 72,325,455
• 10 Day Avg. Volume: 1,338,181
• 30 Day Avg. Volume: 852,477
• PEG Ratio: 0.05
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 3.65
• P/FCF Ratio: 7.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.88
• Revenue Forecast (FY): €54.75M

• Rating: 51 Neutral
• Price Target: €3.00 ▼(-22.28% Downside)
• Action: Reiterated Date: 12/07/25
• Date: Action: Reiterated 12/07/25

Cellectis SA's overall stock score reflects strong technical momentum but is weighed down by financial performance challenges and unattractive valuation metrics. The company's revenue growth is a positive factor, but significant profitability and cash flow issues, along with increased leverage, pose risks. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strong revenue growth

Sustained, double‑digit revenue expansion indicates expanding demand for Cellectis' products and collaboration services. Durable top‑line momentum supports continued partner funding, milestone receipts and increases likelihood of achieving scale needed to absorb fixed R&D costs over months.

Very high gross margin

A 92% gross margin implies highly efficient direct cost structure for the company’s core technologies. That structural margin advantage provides long‑term leverage as revenues scale, improving potential to fund R&D and commercial investments while preserving unit economics post‑commercialization.

Proprietary TALEN tech & collaboration model

Owning differentiated TALEN genome‑editing IP plus a collaborator/licensing revenue model creates a durable business mix: non‑dilutive partner funding, milestone cadence and potential royalties. This reduces sole reliance on product sales during clinical development and strengthens long‑term upside.

Negative Factors

Negative profitability margins

Persistent negative EBIT and net margins show the company has not yet converted scientific progress into profitable operations. Over a multi‑month horizon this reduces retained earnings, increases reliance on external funding, and pressures the timeline for sustainable operating profitability.

Weak cash generation

Negative free cash flow growth and poor operating cash conversion indicate the business struggles to turn reported results into usable cash. Structurally weak cash generation raises refinancing and dilution risk and limits the firm's capacity to self‑fund expensive clinical programs.

Increased leverage

A near‑1.0 debt/equity ratio and modest equity base increase financial risk if profits do not materialize. Higher leverage constrains flexibility for R&D or acquisitions, raises interest and refinancing exposure, and can magnify downside during extended development timelines.

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

How the Company Makes Money

Cellectis generates revenue through a combination of research collaborations, licensing agreements, and potential milestone payments from partnerships with larger pharmaceutical companies. The company enters into strategic collaborations to leverage its gene editing technology for developing new therapies, which often includes upfront payments and milestone payments tied to achieving specific development goals. Additionally, Cellectis may earn royalties on any commercialized products that result from these partnerships. The company also focuses on advancing its proprietary product candidates, which could contribute to revenue streams through future sales once they reach the market.

Cellectis SA Financial Statement Overview

Summary

Cellectis SA shows strong revenue growth but faces significant profitability and cash flow challenges. The high gross profit margin indicates operational efficiency, yet negative net profit and EBIT margins highlight ongoing financial difficulties. Increased leverage and cash flow issues suggest a need for strategic adjustments to enhance financial stability.

Income Statement

Cellectis SA shows a mixed performance in its income statement. The company has experienced significant revenue growth in the TTM period, with a 33.7% increase, indicating strong sales momentum. However, profitability remains a concern, as evidenced by negative net profit and EBIT margins, reflecting ongoing operational challenges. The gross profit margin is high at 92.11%, suggesting efficient cost management in production, but the overall negative margins highlight the need for better cost control and revenue generation strategies.

Balance Sheet

The balance sheet of Cellectis SA reveals a moderate financial position. The debt-to-equity ratio has increased to 0.98 in the TTM period, indicating higher leverage and potential risk if earnings do not improve. The equity ratio stands at 29.3%, showing a reasonable level of equity financing. However, the return on equity is negative, reflecting the company's inability to generate profits from its equity base. This suggests a need for strategic improvements to enhance shareholder value.

Cash Flow

Cellectis SA's cash flow statement highlights challenges in cash generation. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is also negative, indicating cash flow issues. Despite a positive free cash flow to net income ratio, the overall cash flow situation suggests the company struggles to convert its operations into cash, which could impact its ability to fund future growth without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	75.27M	41.51M	755.00K	19.17M	73.95M	73.95M
Gross Profit	68.47M	41.51M	18.00K	17.40M	37.67M	37.67M
EBITDA	-6.07M	-9.46M	-92.64M	-76.38M	-85.44M	-43.34M
Net Income	-35.35M	-36.76M	-101.06M	-98.69M	-86.28M	-72.57M
Balance Sheet
Total Assets	343.05M	383.54M	334.27M	261.22M	382.08M	469.47M
Cash, Cash Equivalents and Short-Term Investments	190.22M	260.31M	203.81M	97.70M	186.13M	268.24M
Total Debt	92.78M	91.46M	85.06M	82.85M	102.24M	111.30M
Total Liabilities	242.57M	252.51M	249.57M	135.28M	145.60M	160.63M
Stockholders Equity	100.48M	131.03M	84.69M	117.97M	221.29M	275.57M
Cash Flow
Free Cash Flow	-32.71M	19.15M	-25.82M	-89.89M	-124.31M	-126.52M
Operating Cash Flow	-29.09M	22.99M	-24.75M	-87.44M	-104.56M	-80.26M
Investing Cash Flow	-68.60M	-102.81M	-15.51M	-2.76M	7.28M	-54.34M
Financing Cash Flow	-9.70M	89.11M	82.86M	1.15M	47.52M	27.32M

Cellectis SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Negative. The current price of 3.86 is above the 20-day moving average (MA) of 3.35, above the 50-day MA of 3.41, and above the 200-day MA of 2.92, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 41.09 is Neutral, neither overbought nor oversold. The STOCH value of 20.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCLS.

Cellectis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALSEN	55 Neutral	€352.08M	-1.46	-40.00%	―	―	10.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALCLS	51 Neutral	€224.21M	117.92	-30.75%	―	150.80%	67.81%
NANO	49 Neutral	€1.42B	-9.10	―	―	―	―
OSE	49 Neutral	€82.86M	-1.87	-52.76%	―	-96.92%	-175.84%
IPH	47 Neutral	€115.31M	-1.52	-658.91%	―	-75.86%	-30.54%
TNG	43 Neutral	€210.91M	-1.48	-634.16%	―	111.76%	-22.45%